Talzenna (Talazoparib)
| Dose | Size & Price | Qty |
|---|
-
Description
-
Reviews (0)
-
Related Products
-
Related Conditions
Fact Table
| Fact Table | |
|---|---|
| Formula | C19H14F2N6O |
| License | FDA approved October?2018 for gBRCA-mutated HER2-negative locally advanced or metastatic breast cancer; also approved in other jurisdictions. :contentReference[oaicite:2]{index=2} |
| Bioavailability | Oral bioavailability not specifically quantified in label; dose is 1?mg once daily. :contentReference[oaicite:3]{index=3} |
| Legal status | Prescription only (Rx) in US, Canada, EU. :contentReference[oaicite:4]{index=4} |
| Chemical Name | (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one :contentReference[oaicite:5]{index=5} |
| Elimination half-life | ~90?hours (±58?h) reported in some sources. :contentReference[oaicite:6]{index=6} |
| Dosage (Strength) | Capsules available: 0.25?mg, 0.5?mg, 0.75?mg, and 1?mg; recommended starting dose 1?mg once daily with or without food. :contentReference[oaicite:7]{index=7} |
| Pregnancy | Can cause fetal harm; use effective contraception for females of reproductive potential and advise males accordingly. :contentReference[oaicite:8]{index=8} |
| Brands | Talzenna® (Pfizer) :contentReference[oaicite:9]{index=9} |
| Protein binding | ~74% (according to some sources) :contentReference[oaicite:10]{index=10} |
| PubChem CID | 135565082 :contentReference[oaicite:11]{index=11} |
| MedlinePlus | a618070 :contentReference[oaicite:12]{index=12} |
| ChEBI | Not clearly listed separately in many sources :contentReference[oaicite:13]{index=13} |
| ATC code | L01XK04 :contentReference[oaicite:14]{index=14} |
| DrugBank | DB11760 :contentReference[oaicite:15]{index=15} |
| KEGG | D10732 (also D10733) :contentReference[oaicite:16]{index=16} |
| Routes of administration | By mouth (oral capsules) :contentReference[oaicite:17]{index=17} |
Talzenna (Talazoparib) is an oral poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. The medication functions by inhibiting PARP enzymes, which play a key role in DNA repair. By blocking this pathway, Talzenna promotes cancer cell death, particularly in cells with deficient BRCA1/2 function.
Approved by the FDA, Talzenna is part of a targeted therapy approach aimed at exploiting specific genetic vulnerabilities in cancer cells, providing a personalized treatment option for eligible patients.
Directions
Talzenna is administered orally, typically once daily, with or without food. The recommended starting dose is 1 mg taken at the same time each day. Treatment should continue until disease progression or unacceptable toxicity occurs. Dose adjustments may be necessary based on individual tolerability, renal function, or in the presence of adverse reactions.
Healthcare professionals should determine the appropriate duration and any dose modifications. Patients are advised not to crush, chew, or split the capsules.
Ingredients
Each capsule of Talzenna contains the active ingredient Talazoparib tosylate, which is equivalent to Talazoparib. Inactive ingredients include lactose monohydrate, microcrystalline cellulose, magnesium stearate, and other excipients used in capsule formulation. The capsule shell contains gelatin, titanium dioxide, and iron oxides, depending on the dosage strength.
Cautions
Caution is advised in patients with moderate to severe renal impairment, as dose modifications may be necessary. Talzenna can cause myelosuppression, including anemia, neutropenia, and thrombocytopenia, requiring periodic monitoring of complete blood counts. Embryo-fetal toxicity is a serious concern; female patients of reproductive potential should use effective contraception during treatment and for at least seven months after the last dose.
Drug interactions, particularly with P-gp inhibitors or inducers, may affect Talazoparib plasma levels. A thorough review of the patient's medication regimen is advised to prevent adverse interactions.
Contraindications
Talzenna is contraindicated in patients with a known hypersensitivity to Talazoparib or any component of the formulation. Use is not recommended during pregnancy due to the potential for fetal harm. It should not be used concurrently with strong P-glycoprotein (P-gp) inhibitors without appropriate dose adjustments.
Side Effects
Common and serious side effects reported with Talzenna include:
- Anemia
- Fatigue
- Nausea
- Neutropenia
- Thrombocytopenia
- Headache
- Diarrhea
- Vomiting
- Decreased appetite
- Dizziness
- Insomnia
Periodic laboratory monitoring and clinical assessments are recommended to manage these effects.
Frequently Asked Questions about Talzenna (Talazoparib)
What is Talzenna used for?
Talzenna is an oral medication used to treat adults with HER2-negative breast cancer that has a germline BRCA mutation and is either locally advanced or metastatic. It may be used alone or in combination with other therapies, depending on the treatment plan.
How does Talzenna work?
Talzenna is a PARP inhibitor that works by blocking an enzyme cancer cells use to repair DNA damage. In BRCA-mutated cancer cells, this leads to cell death, slowing or stopping tumor growth.
How is Talzenna taken?
Talzenna is taken orally once daily, with or without food. It should be swallowed whole and not crushed, chewed, or opened. Dosing may vary depending on the specific condition being treated and individual tolerability.
What are common side effects of Talzenna?
Common side effects include fatigue, nausea, vomiting, decreased appetite, anemia, neutropenia, and headache. Some patients may also experience taste changes or diarrhea during treatment.
Can Talzenna cause serious side effects?
Yes, serious risks include severe bone marrow suppression (anemia, neutropenia, thrombocytopenia), myelodysplastic syndrome, and acute myeloid leukemia. Regular blood tests are required to monitor for these conditions.
Who should not take Talzenna?
Talzenna is not recommended for individuals with hypersensitivity to talazoparib or any of its components. Patients with existing severe bone marrow suppression or untreated infections should be evaluated carefully before starting treatment.
How long does it take for Talzenna to start working?
The time to response varies, but some patients may begin to see effects within a few weeks to months. Continued use and regular imaging tests are needed to assess effectiveness over time.
Are there drug interactions with Talzenna?
Yes, Talzenna may interact with P-glycoprotein inhibitors or inducers, which can affect its absorption and levels in the body. Patients should inform their healthcare provider of all medications, including over-the-counter products and supplements.
What should I do if I miss a dose of Talzenna?
If a dose is missed, it should be taken as soon as remembered the same day. If it's the next day, skip the missed dose and resume the regular schedule. Do not take two doses at once.
Can Talzenna be used during pregnancy or breastfeeding?
Talzenna can cause harm to an unborn baby and should not be used during pregnancy. Effective contraception is recommended during treatment and for a period afterward. Breastfeeding is not advised while on Talzenna and for at least one week after the final dose.
